{Title}

Bio€quity Europe | 2018

the seminal industry event for financial dealmakers



May 14 - 16, 2018 | Ghent, Belgium

Ghent Travel & Hotel Information

City Hall (Monday Evening Event)

Monday, May 14, 17:30 — 20:30 — Bio€quity Europe Organizers Welcome and Opening Plenary Session: A Fireside Chat with Belgian innovators followed by a Welcome Reception

Het Pand (Main Event on Tuesday and Wednesday) Ghent, Belgium


At Capacity. Join the Wait List.

Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected Presenting Companies.

Now celebrating its 19th meeting, Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals.

Delegates from 24 nations attended Bio€quity Europe last year in Paris.


Return to Conferences List
SCHEDULE
Bio Globalization Hits Home – Is Europe Caught in the Middle?

Over nearly two decades, Bio€quity Europe has debated Europe’s relationship to the U.S. on scientific achievement, corporate leadership and access to capital. In 2018, Bio€quity Europe turns to the East, challenging both biotech innovators and investors to face the consequences of a fast-rising Asia on one side and the continuing leadership set by U.S. on the other.

5:30 PM to 5:45 PM
Bio€quity Europe Organizers Welcome
City Hall / Pacificatiezaal
  • Mathias De Clercq, Senior Deputy Mayor and Deputy Mayor of the Port, Economy and Enterprise, City of Ghent
  • David Flores, President & CEO, BioCentury
  • Christophe Peeters, Vice Mayor, Retail, Festivities, Finance and Innovation, City of Ghent
  • Pam Putz, Managing Director, EBD Group
  • David Thomas, Senior Director, Industry Research and Policy Analysis at Biotechnology Innovation Organization
5:45 PM to 7:00 PM
Opening Session - Fireside Chat with Belgian Pathfinders on Resilience and Building Global Value
City Hall / Pacificatiezaal
8:50 AM to 9:00 PM
Bio€quity Europe Opens with Euronext Bell Ringing Ceremony
Level 2, Zaal Rector Vermeylen
  • Anna Chrisman, Group Managing Director, EBD Group
  • David Flores, President & CEO, BioCentury
  • Vincent Van Dessel, CEO and Chairman Euronext Brussels
  • Dirk Reyn, Vice Chairman, flanders.bio
9:15 AM to 10:15 AM
Plenary 1 – Bio Globalization Hits Home: How Should Europe Respond?
Level 2, Zaal Rector Vermeylen

Asia’s rush into biotech provides new opportunity, new capital – and competition – for European innovators who have been focused on the U.S. What should European life science leaders be thinking about Asia’s commitment to invigorate life sciences innovation, prioritize regulatory modernization and build a high-energy startup ecosystem?

Moderator: Josh Berlin, Executive Director, New Ventures, BioCentury

  • Roel Bulthuis, Head, M Ventures
  • Franck Le Deu, Senior Partner & Head of Greater China Healthcare Practice, McKinsey
  • Nanna Lüneborg Ph.D., Partner, Novo Ventures
  • Jörg Neermann Ph.D, Partner, LSP
  • Antoine Papiernik, Chairman & Managing Partner, Sofinnova
  • Patrick van Beneden, Partner, Healthcare, Gimv
10:15 AM to 11:15 AM
Plenary 2 - Bio Globalization Hits Home: Where Can Europe Lead in Strategic R&D?
Level 2, Zaal Rector Vermeylen

Where is European science and biotech going to lead as genomics and regenerative medicine gather steam globally?

Moderator: C. Simone Fishburn Ph.D., Vice President & Executive Editor, BioCentury

  • Joanne Hackett Ph.D, CCO, Genomics England
  • Tim Haines, Managing Partner, Abingworth
  • Bernd Stowasser Ph.D., Head Global Public Private Partnerships and R&D Alliance Management, Sanofi
  • Mirko Scherer, Ph.D., Managing Partner, TVM Capital China
  • John Tchelingerian, Ph.D., CEO, Promethera
  • Nathalie ter Wengel M.D., European Head External Science and Innovation, Pfizer
11:00 AM to 11:10 AM
Cardior Pharmaceuticlas GmbH
Level 1, Rector Gillis
11:00 AM to 11:20 AM
MC2 Therapeutics A/S
Level 1+, Priorzaal
11:10 AM to 11:20 AM
Aelin Therapeutics
Level 1, Rector Gillis
11:20 AM to 11:30 AM
Atriva Therapeutics GmbH
Level 1, Rector Gillis
11:20 AM to 11:40 AM
Acesion Pharma ApS
Level 1+, Priorzaal
11:30 AM to 12:30 PM
Biotech CEO Workshop 8.0: What European CEOs Need To Know To Attract U.S. Capital
Level 2, Zaal Rector Vermeylen

What do U.S. VCs need to see in order to put money into European Start Ups? This panel of VCs and executives debate what’s need to overcome ‘gating’ factors for U.S. investment in Europe

  • Carole Nuechterlein, Partner, Roche Venture Fund
  • Florian Fischer, CFO, Affimed N.V.
  • Chris Hollowood, Ph.D., Chief Investment Officer and a Managing Partner, Syncona Investment Management
  • Ravi Mehrotra Ph.D., Partner, MTS Health Partners
  • Bibhash Mukhopadhyay Ph.D., Principal, NEA
  • Henrijette Richter Ph.D., Managing Partner, Sofinnova Partners
11:30 AM to 11:40 AM
Glycostem Therapeutics
Level 1, Rector Gillis
11:40 AM to 11:50 AM
Minoryx Therapeutics S.L.
Level 1, Rector Gillis
11:40 AM to 12:00 PM
Vaximm AG
Level 1+, Priorzaal
11:50 AM to 12:00 PM
Tusk Therapeutics Ltd.
Level 1, Rector Gillis
12:00 PM to 12:10 PM
Heparegenix GmbH
Level 1, Rector Gillis
12:00 PM to 12:20 PM
Newron Pharmaceuticals S.p.A. (SIX:NWRN)
Level 1+, Priorzaal
12:10 PM to 12:20 PM
Artios Pharma Ltd.
Level 1, Rector Gillis
12:20 PM to 12:40 PM
Nouscom AG
Level 1+, Priorzaal
12:20 PM to 12:30 PM
Novintum Bioscience Ltd.
Level 1, Rector Gillis
2:00 PM to 3:10 PM
What Are Chinese Investors Looking for in European Assets?
Room: Level 2+, Oude Infirmerie

Inaugural China-Europe Showcase (Hosted by BioCentury and BayHelix)

Flush with cash and driven by government reforms to invigorate life sciences innovation, Chinese VCs and corporate strategics are hunting for assets in Europe. These top investors explain how European biotechs can position themselves to take advantage of new financing opportunities from China.

Co-Moderators: Speakers:

  • David Flores, President and CEO, BioCentury
  • Kewen JIN, M.D., Managing Director, Serica Capital
  • Sean Cao, Ph.D., Managing Director, C-Bridge Capital
  • Leon Chen, Ph.D., CEO, 6 Dimensions Capital
  • Ting JIA “TJ”, Ph.D., Managing Director, Hillhouse Capital Management
  • Yuwen LIU, Founding Partner, Bohe Angel Fund
  • Huaizheng PENG, M.D., Ph.D., Managing Director, CMS Medical Venture Investment Ltd.
2:00 PM to 2:10 PM
Horama S.A.
Level 1, Rector Gillis
2:00 PM to 2:20 PM
Cell Medica Ltd.
Level 1+, Priorzaal
2:10 PM to 2:20 PM
Imcyse S.A.
Level 1, Rector Gillis
2:20 PM to 2:30 PM
Immune Biosolutions Inc.
Level 1, Rector Gillis
2:20 PM to 2:40 PM
IO Biotech ApS
Level 1+, Priorzaal
2:30 PM to 3:30 PM
Is Europe Ready for Growth Capital Funds?
Level 2, Zaal Rector Vermeylen

To reach bellwether status, European biotechs need capital to grow beyond clinical proof of concept. But the dearth of specialist growth capital forces European innovators to look to the US, and increasingly toward pools of Asian money looking for commercial opportunities. Is it time for European funds to provide a homegrown solution, or cede the space to offshore money? Or does geography for growth capital matter less than early stage investments?

Moderator: Paul Hadden, Partner, HealthCare Royalty Partners

  • Alain Baetens, Head of Listings, Belgium, Euronext
  • Chris De Jonghe Ph.D, Head of Life Sciences & Care, Group Manager Venture Capital, PMV
  • Michele Ollier, M.D., Partner, Medicxi
  • Gilles Nobécourt, Partner, Andera Partners
  • Greg Parekh Ph.D, Partner, New Rhein Healthcare Investors
  • Graziano Seghezzi, Managing Partner, Sofinnova Partners
  • Thomas Stockman, Managing Director, Healthcare, RBC Capital Markets
2:30 PM to 2:40 PM
Inthera Bioscience AG
Level 1, Rector Gillis
2:40 PM to 2:50 PM
Apteeus S.a.r.l.
Level 1, Rector Gillis
2:50 PM to 3:00 PM
Ducentis BioTherapeutics Ltd.
Level 1, Rector Gillis
3:00 PM to 3:10 PM
Camel-IDS N.V.
Level 1, Rector Gillis
3:00 PM to 3:20 PM
Promethera Biosciences S.A.
Level 1+, Priorzaal
3:10 PM to 3:20 PM
Medherant Ltd.
Level 1, Rector Gillis
3:15 PM to 4:30 PM
China Case Studies: Lessons Learned from European Deals
Room: Level 2+, Oude Infirmerie

Inaugural China-Europe Showcase (Hosted by BioCentury and BayHelix)

This case study session dissects the drivers of the Chinese attraction to Europe, and how European biotech need to approach these new opportunities.

Moderator: Jorge Santos da Silva Ph.D., Partner, McKinsey & Co.

  • Bianca Ahrens, Ph.D., Scientific Director, Business Development & Portfolio Management, MorphoSys AG
  • Stephan Lensky, Ph.D., COO/CBO, EpiMab Biotherapeutics Inc.
  • Ji LI, Ph.D., Global Head of Business Development, BeiGene Ltd.
  • Mai-Jing LIAO, Ph.D., SVP, Head of Business Development and Portfolio Management, Harbour BioMed
  • Donald Wyatt, VP of Business Development &. Alliance Management, 3SBio Inc.
3:20 PM to 3:30 PM
Molecular Targeted Radiopharmaceuticals SA
Level 1, Rector Gillis
3:20 PM to 3:40 PM
NBE-Therapeutics AG
Level 1+, Priorzaal
3:30 PM to 3:40 PM
OncoDNA S.A.
Level 1, Rector Gillis
3:40 PM to 3:50 PM
Iproteos S.L.
Level 1, Rector Gillis
3:40 PM to 4:00 PM
Addex Therapeutics Ltd.
Level 1+, Priorzaal
3:45 PM to 5:15 PM
PRE-SEED SHOWCASE 1
Level 2, Zaal Rector Vermeylen

Selected Pre-Seed Companies present to a diverse panel of Bio€quity Europe ‘judges’ who provide high level feedback on their business plan, presentation and overall strategy.

Moderator: Eric Pierce, Publisher, BioCentury

Judges: Pre-Seed Companies:

  • Karen Bernstein Ph.D., Chairman, BioCentury
  • Alicia Irurzun-Lafitte, Principal, M Ventures
  • JR Rothe Ph.D, Managing Partner, LSP
  • Nico Vandervelpen, Managing Director Bioqube Ventures
  • Inositec AG (15:45)
  • Proteodesign (16:00)
  • TolerogenixX (16:15)
  • Proteinlogic (16:30)
  • NeoPhore Ltd. (16:45)
  • Draupnir Bio (17:00)
3:50 PM to 4:00 PM
PDC*line Pharma
Level 1, Rector Gillis
4:00 PM to 4:10 PM
Topas Therapeutics GmbH
Level 1, Rector Gillis
4:00 PM to 4:20 PM
BerGenBio ASA (OSLO:BGBIO)
Level 1+, Priorzaal
4:10 PM to 4:20 PM
Novadiscovery
Level 1, Rector Gillis
4:20 PM to 4:30 PM
Step Pharma S.A.S.
Level 1, Rector Gillis
4:20 PM to 4:40 PM
Actinium Pharmaceuticals Inc.
Level 1+, Priorzaal
4:30 PM to 4:40 PM
Evox Therapeutics Ltd.
Level 1, Rector Gillis
4:40 PM to 5:00 PM
eTheRNA immunotherapies N.V.
Level 1+, Priorzaal
4:40 PM to 4:50 PM
Xbrane Biopharma AB
Level 1, Rector Gillis
4:50 PM to 5:00 PM
HIL Applied Medical
Level 1, Rector Gillis
5:00 PM to 5:20 PM
ThromboGenics N.V. (Euronext Brussels:THR)
Level 1+, Priorzaal
CureVac AG
Level 2+, Oude Infirmerie
Forendo Pharma Oy
Level 1, Rector Gillis
5:20 PM to 5:40 PM
Reapplix ApS
Level 1, Rector Gillis
Verona Pharma plc (LSE:VRP; NASDAQ:VRNA)
Level 1+, Priorzaal
Genkyotex S.A. (Euronext:GKTX)
Level 2+, Oude Infirmerie
5:40 PM to 6:00 PM
GamaMabs Pharma S.A.
Level 1, Rector Gillis
PCI Biotech Holding ASA (OSE:PCIB)
Level 2+, Oude Infirmerie
Curetis N.V.
Level 1+, Priorzaal
6:00 PM to 6:20 PM
Heidelberg Pharma AG
Level 1+, Priorzaal
Acacia Pharma Group plc
Level 2+, Oude Infirmerie
7:00 PM to 10:30 PM
Evening Reception and Entertainment

Feestzalen Oude Vismijn Sint-Veerleplein 5, Ghent

9:00 AM to 10:10 AM
PRE-SEED SHOWCASE 2
Level 2, Zaal Rector Vermeylen

Selected Pre-Seed Companies present to a diverse panel of Bio€quity Europe ‘judges’ who provide high level feedback on their business plan, presentation and overall strategy.

Moderator: Eric Pierce, Publisher, BioCentury

Judges: Pre-Seed Companies:

  • Sean Cao, Ph.D., Managing Director, C-Bridge Capital
  • Emmanuelle Coutanceau, Ph.D. Partner, Novo Seeds
  • Emmanuel Lacroix, Ph.D. Senior Director, Venture Investments, UCB Ventures
  • Vanessa Malier, Managing Partner, Kurma Partners
  • ADCendo Aps (9:00)
  • Roscue (9:15)
  • Abarceo Pharma AB (9:30)
  • Polyneuron Pharmaceuticals (9:45)
9:00 AM to 9:20 AM
Affimed N.V. (NASDAQ:AFMD)
Level 1+, Priorzaal
9:00 AM to 9:10 AM
InteRNA Technologies B.V.
Level 1, Rector Gillis
9:10 AM to 9:20 AM
Storm Therapeutics Ltd.
Level 1, Rector Gillis
9:20 AM to 9:30 AM
Rejuvenate Biomed NV
Level 1, Rector Gillis
9:20 AM to 9:40 AM
Probiodrug AG (Euronext:PBD)
Level 1+, Priorzaal
9:30 AM to 9:40 AM
Softhale N.V.
Level 1, Rector Gillis
9:40 AM to 9:50 AM
Biognosys AG
Level 1, Rector Gillis
9:40 AM to 10:00 AM
Realm Therapeutics plc (LSE:RLM)
Level 1+, Priorzaal
Oryzon Genomics S.A.
Level 2+, Oude Infirmerie
9:50 AM to 10:00 AM
Rewind Therapeutics
Level 1, Rector Gillis
10:00 AM to 10:10 AM
GammaDelta Therapeutics Ltd.
Level 1, Rector Gillis
10:00 AM to 10:20 AM
BeyondSpring Inc. (NASDAQ:BYSI)
Level 1+, Priorzaal
Asceneuron S.A.
Level 2+, Oude Infirmerie
10:10 AM to 10:20 AM
Octimet Oncology NV
Level 1, Rector Gillis
10:20 AM to 11:20 AM
Biotech Building Blocks Panel - How to go from Series B to Bellwether
Level 2, Zaal Rector Vermeylen

What C-level teams of European private biotechs need to put in place to become the next bellwether. This panel will discuss and debate what management teams of private companies need to put in place from shareholder and board level communications to control of assets and partnering.

Moderator: Jan De Kerpel Ph.D, Managing Director, Kempen & Co.

Speakers:

  • Joe Anderson Ph.D., CEO, Arix Bioscience
  • Gil Beyen, Chairman & CEO, Erytech Pharma
  • Ulrich Dauer Ph.D., CEO, Probiodrug AG
  • Arthur Franken, Partner, Gilde
  • Marina Udier Ph.D, COO, Nouscom AG
10:20 AM to 10:40 AM
iTeos Therapeutics S.A.
Level 1+, Priorzaal
Immunicum AB (SSE:IMMU)
Level 2+, Oude Infirmerie
10:30 AM to 10:40 AM
Mikro Biyosistemler Inc.
Level 1, Rector Gillis
10:40 AM to 11:00 AM
Complix N.V.
Level 1+, Priorzaal
OxThera AB
Level 2+, Oude Infirmerie
10:40 AM to 10:50 AM
Ability Pharmaceuticals S.L.
Level 1, Rector Gillis
10:50 AM to 11:00 AM
Confo Therapeutics N.V.
Level 1, Rector Gillis
11:00 AM to 11:20 AM
Sorrento Therapeutics (Nasdaq:SRNE)
Level 1+, Priorzaal
BioClin Therapeutics Inc.
Level 2+, Oude Infirmerie
11:20 AM to 12:20 PM
New Pathways for financing EU startups
Level 2, Zaal Rector Vermeylen

Where early stage investors are playing in Europe what that could mean for your next fundraising round. Also how are investors prioritizing investment in brick and mortar companies versus more virtual models and spin-outs of deprioritized assets from Big Pharma?

Moderator: Christina Takke Ph.D, Managing Partner, V-Bio Ventures

  • Jeanne Bolger, Ph.D, Vice President, Venture Investments, Johnson & Johnson Development Corp.
  • Johan Cardoen, Ph.D, Managing Director, VIB
  • Hakan Goker, Ph.D., Senior Investment Director, M Ventures
  • Frank Kalkbrenner, Ph.D, Head, Boehringer Ingelheim Venture Fund
  • Vanessa Malier, Managing Partner, Kurma Partners
  • Erica Whittaker, Ph.D, Head of UCB Ventures
11:20 AM to 11:40 AM
reMYND N.V.
Level 2+, Oude Infirmerie
PsiOxus Therapeutics Ltd.
Level 1+, Priorzaal
11:40 AM to 12:00 PM
Affibody AB
Level 1+, Priorzaal
Synaffix B.V.
Level 2+, Oude Infirmerie
12:00 PM to 12:20 PM
Erytech Pharma S.A. (NASDAQ:ERYP)
Level 1+, Priorzaal
Noxxon Pharma N.V. (Euronext:ALNOX)
Level 2+, Oude Infirmerie
12:20 PM to 12:40 PM
Bone Therapeutics S.A. (Euronext:BOTHE)
Level 1+, Priorzaal
Saniona AB (SSE:SANION)
Level 2+, Oude Infirmerie
2:00 PM to 3:20 PM
REGIONAL HOST SESSION
Level 2, Zaal Rector Vermeylen

Belgian Pitch Session

  • Gert Vanhees, Partner, Deloitte
  • Elke Janssens, Partner, Nautadutilh
  • Willem Broekaert, PhD, Managing Partner, V-Bio Ventures
  • Jan Van den Bossche, Partner, Fund+
  • Griet Van Poucke, PhD, Manager New Ventures, VIB
  • Nico Vandervelpen, Managing Partner, BioQube Ventures
  • Sylvie Ponchaut, PhD, Managing Director, BioWin
  • Katya Smirnyagina, PhD, Partner, Capricorn Venture Partners
  • Companies:
  • AgomAb Therapeutics
  • Aphea.bio
  • Confo Therapeutics
  • Ontoforce
  • Universiteit Gent
  • VIB
  • Vipun Medical
2:00 PM to 2:20 PM
Centogene AG
Level 1+, Priorzaal
Herantis Pharma plc
Level 1, Rector Gillis
2:20 PM to 2:40 PM
Exicure Inc.
Level 1, Rector Gillis
Targovax A/S
Level 1+, Priorzaal
2:40 PM to 3:00 PM
Kiadis Pharma N.V. (Euronext:KDS)
Level 1+, Priorzaal
Numab Therapeutics AG
Level 1, Rector Gillis